NSTL国家科技图书文献中心

1. Beyond fat: Does semaglutide affect lean mass? NSTL国家科技图书文献中心

Jamialahmadi, Tannaz | Eid, Ali H.... - 《Clinical nutrition》 - 2025,44 - 104～108 - 共5页

摘要： influence of semaglutide, a glucagon-like peptide-1 | is achieved with semaglutide, the impact of this | investigations have demonstrated that semaglutide-induced | semaglutide. This disparity in research findings emphasizes | because semaglutide* use is rising quickly. (c) 2024*

关键词： Semaglutide | Glucagon-like peptide-1 receptor agonist | Body composition | Lean mass

2. Semaglutide protects against diabetes-associated cardiac inflammation via Sirt3-dependent RKIP pathway NSTL国家科技图书文献中心

Lin, Kaibin | Wang, Ai ... - 《British journal of pharmacology.》 - 2025,182(7) - 1561～1581 - 共21页

摘要： mechanisms remain incompletely understood. Semaglutide, a | the therapeutic potential of semaglutide* in diabetic* | diet/streptozotocin were treated with semaglutide | effects of semaglutide* were analysed using animal and* | , semaglutide* alleviated metabolic disorders, ameliorated*

关键词： diabetes mellitus | heart failure | inflammation | RKIP | semaglutide

3. Effectiveness and Safety of Semaglutide for Weight Loss in Patients With Inflammatory Bowel Disease and Obesity NSTL国家科技图书文献中心

Desai, Aakash | Khataniar, Himsikhar ... - 《Inflammatory bowel diseases》 - 2025,31(3) - 696～705 - 共10页

摘要：Background: Semaglutide, a glucagon-like | from initiation of semaglutide* compared with baseline* | -specific outcomes with and without semaglutide* use in* | semaglutide (mean age 47.4 +/- 12.2 years; mean TBW 237 | mean TBW change after initiation of semaglutide* in*

关键词： semaglutide | obesity | inflammatory bowel disease

4. Effect of semaglutide with obesity or overweight individuals without diabetes: an Umbrella review of systematic reviews NSTL国家科技图书文献中心

Hu, Xiaoye | Wang, Yongsheng ... - 《Endocrine.》 - 2025,88(2) - 387～397 - 共11页

摘要： safety of Semaglutide* for non-diabetic obese patients* | meta-analysis of semaglutide* in non-diabetic obesity* | 10 RCTs, revealing that semaglutide* induced average* | rates significantly increased. Semaglutide* also* | obesity. However, Recent studies show semaglutide* can*

关键词： Semaglutide | Overweight | Obesity | Umbrella review | Diabetes

5. Efficacy and Safety of Semaglutide in Weight Loss Non-diabetic People NSTL国家科技图书文献中心

Song, Cai-E | Wang, Yan ... - 《Endocrine, metabolic & immune disorders drug targets》 - 2025,25(3) - 215～221 - 共7页

摘要： efficacy and safety of semaglutide* in weight loss in non* | people who used semaglutide* to lose weight in the* | semaglutide 0.25 mg, 0.5 mg, 0.75 mg, or 1 mg subcutaneously | hypotension, was observed. Conclusion Low-dose semaglutide | Objective The study aimed to investigate the

关键词： Obesity | overweight | semaglutide | weight loss

6. The blood pressure-lowering property of subcutaneous semaglutide: a systematic review, meta-analysis, and meta-regression NSTL国家科技图书文献中心

Ala, Moein | Aleaba, Mohammadreza... - 《Journal of endocrinological investigation.》 - 2025,48(2) - 283～294 - 共12页

摘要： clinical trials reported that subcutaneous semaglutide | and 18,231 participants in the semaglutide* group* | were included in this study. Subcutaneous semaglutide | pressure-lowering property of subcutaneous semaglutide | semaglutide more than 1 mg/week, baseline systolic blood

关键词： Semaglutide | Meta-analysis | Blood pressure | Diabetes | Obesity | Weight loss

7. Evaluating semaglutide + LAI-287 (IcoSema) for the treatment of diabetes mellitus type II NSTL国家科技图书文献中心

Siamashvili, Maka | Davis, Stephen N. - 《Expert opinion on pharmacotherapy》 - 2025,26(1) - 1～7 - 共7页

摘要： semaglutide. The key trials from the clinical development | process of insulin icodec, semaglutide, and IcoSema are | IntroductionA stepwise coordinated multiple | therapeutic targeted approach to the treatment of type 2 | diabetes includes starting with lifestyle modification

关键词： IcoSema | diabetes | semaglutide | icodec | insulin

8. Effects of Semaglutide on Muscle Structure and Function in the SLIM LIVER Study NSTL国家科技图书文献中心

Grace L,Ditzenberger | Jordan E,Lake ... - 《Clinical infectious diseases》 - 2025,80(2) - 389～396 - 共8页

摘要：Abstract Background Semaglutide* is highly* | A5371) study, a single-arm study of semaglutide* in* | semaglutide for 24 weeks (titrated to 1 mg/week by week 4 | ).Conclusions In PWH receiving semaglutide* for MASLD, despite* | effective for decreasing weight. Concomitant loss of

关键词： obesity | muscle | function | HIV | semaglutide

9. US Population Eligibility and Estimated Impact of Semaglutide Treatment on Obesity Prevalence and Cardiovascular Disease Events NSTL国家科技图书文献中心

Nathan D.,Wong | Hridhay,Karthikeyan ... - 《Cardiovascular drugs and therapy》 - 2025,39(1) - 75～84 - 共10页

摘要：Abstract Background Semaglutide* 2.4 mg* | estimated the US population eligibility for semaglutide | estimate the US eligible population. Semaglutide* weight* | in estimated risks with and without semaglutide | % “after” semaglutide* “treatment” reflecting a 1.81*

关键词： Obesity | Cardiovascular disease | Prevention | Semaglutide | GLP-1 receptor agonists

10. Chitosan hydrochloride coated and nonionic surfactant modified niosomes: a better way for oral administration of semaglutide NSTL国家科技图书文献中心

Wang, Ben | Su, Zhengxing ... - 《Biomedical materials》 - 2025,20(3) - 共12页

摘要： 643 million by the end of 2030. Semaglutide, a human | absorption efficiency of semaglutide* in oral delivery, we* | semaglutide. | Diabetes is now a global chronic disease, with | the number of people with diabetes expected to reach

摘要： influence of semaglutide, a glucagon-like peptide-1 | is achieved with semaglutide, the impact of this | investigations have demonstrated that semaglutide-induced | semaglutide. This disparity in research findings emphasizes | because semaglutide* use is rising quickly. (c) 2024*

关键词： Semaglutide | Glucagon-like peptide-1 receptor agonist | Body composition | Lean mass

摘要： mechanisms remain incompletely understood. Semaglutide, a | the therapeutic potential of semaglutide* in diabetic* | diet/streptozotocin were treated with semaglutide | effects of semaglutide* were analysed using animal and* | , semaglutide* alleviated metabolic disorders, ameliorated*

关键词： diabetes mellitus | heart failure | inflammation | RKIP | semaglutide

摘要：Background: Semaglutide, a glucagon-like | from initiation of semaglutide* compared with baseline* | -specific outcomes with and without semaglutide* use in* | semaglutide (mean age 47.4 +/- 12.2 years; mean TBW 237 | mean TBW change after initiation of semaglutide* in*

关键词： semaglutide | obesity | inflammatory bowel disease

摘要： safety of Semaglutide* for non-diabetic obese patients* | meta-analysis of semaglutide* in non-diabetic obesity* | 10 RCTs, revealing that semaglutide* induced average* | rates significantly increased. Semaglutide* also* | obesity. However, Recent studies show semaglutide* can*

关键词： Semaglutide | Overweight | Obesity | Umbrella review | Diabetes

摘要： efficacy and safety of semaglutide* in weight loss in non* | people who used semaglutide* to lose weight in the* | semaglutide 0.25 mg, 0.5 mg, 0.75 mg, or 1 mg subcutaneously | hypotension, was observed. Conclusion Low-dose semaglutide | Objective The study aimed to investigate the

关键词： Obesity | overweight | semaglutide | weight loss

摘要： clinical trials reported that subcutaneous semaglutide | and 18,231 participants in the semaglutide* group* | were included in this study. Subcutaneous semaglutide | pressure-lowering property of subcutaneous semaglutide | semaglutide more than 1 mg/week, baseline systolic blood

关键词： Semaglutide | Meta-analysis | Blood pressure | Diabetes | Obesity | Weight loss

摘要： semaglutide. The key trials from the clinical development | process of insulin icodec, semaglutide, and IcoSema are | IntroductionA stepwise coordinated multiple | therapeutic targeted approach to the treatment of type 2 | diabetes includes starting with lifestyle modification

关键词： IcoSema | diabetes | semaglutide | icodec | insulin

摘要：Abstract Background Semaglutide* is highly* | A5371) study, a single-arm study of semaglutide* in* | semaglutide for 24 weeks (titrated to 1 mg/week by week 4 | ).Conclusions In PWH receiving semaglutide* for MASLD, despite* | effective for decreasing weight. Concomitant loss of

关键词： obesity | muscle | function | HIV | semaglutide

摘要：Abstract Background Semaglutide* 2.4 mg* | estimated the US population eligibility for semaglutide | estimate the US eligible population. Semaglutide* weight* | in estimated risks with and without semaglutide | % “after” semaglutide* “treatment” reflecting a 1.81*

关键词： Obesity | Cardiovascular disease | Prevention | Semaglutide | GLP-1 receptor agonists

摘要： 643 million by the end of 2030. Semaglutide, a human | absorption efficiency of semaglutide* in oral delivery, we* | semaglutide. | Diabetes is now a global chronic disease, with | the number of people with diabetes expected to reach

关键词： semaglutide | oral delivery | diabetes | penetration enhancers

4008-161-200 800-990-8900

国家科技图书文献中心

摘要： influence of semaglutide, a glucagon-like peptide-1 | is achieved with semaglutide, the impact of this | investigations have demonstrated that semaglutide-induced | semaglutide. This disparity in research findings emphasizes | because semaglutide use is rising quickly. (c) 2024

关键词： Semaglutide | Glucagon-like peptide-1 receptor agonist | Body composition | Lean mass

摘要： mechanisms remain incompletely understood. Semaglutide, a | the therapeutic potential of semaglutide in diabetic | diet/streptozotocin were treated with semaglutide | effects of semaglutide were analysed using animal and | , semaglutide alleviated metabolic disorders, ameliorated

关键词： diabetes mellitus | heart failure | inflammation | RKIP | semaglutide

摘要：Background: Semaglutide, a glucagon-like | from initiation of semaglutide compared with baseline | -specific outcomes with and without semaglutide use in | semaglutide (mean age 47.4 +/- 12.2 years; mean TBW 237 | mean TBW change after initiation of semaglutide in

关键词： semaglutide | obesity | inflammatory bowel disease

摘要： safety of Semaglutide for non-diabetic obese patients | meta-analysis of semaglutide in non-diabetic obesity | 10 RCTs, revealing that semaglutide induced average | rates significantly increased. Semaglutide also | obesity. However, Recent studies show semaglutide can

关键词： Semaglutide | Overweight | Obesity | Umbrella review | Diabetes

摘要： efficacy and safety of semaglutide in weight loss in non | people who used semaglutide to lose weight in the | semaglutide 0.25 mg, 0.5 mg, 0.75 mg, or 1 mg subcutaneously | hypotension, was observed. Conclusion Low-dose semaglutide | Objective The study aimed to investigate the

关键词： Obesity | overweight | semaglutide | weight loss

摘要： clinical trials reported that subcutaneous semaglutide | and 18,231 participants in the semaglutide group | were included in this study. Subcutaneous semaglutide | pressure-lowering property of subcutaneous semaglutide | semaglutide more than 1 mg/week, baseline systolic blood

关键词： Semaglutide | Meta-analysis | Blood pressure | Diabetes | Obesity | Weight loss

摘要： semaglutide. The key trials from the clinical development | process of insulin icodec, semaglutide, and IcoSema are | IntroductionA stepwise coordinated multiple | therapeutic targeted approach to the treatment of type 2 | diabetes includes starting with lifestyle modification

关键词： IcoSema | diabetes | semaglutide | icodec | insulin

摘要：Abstract Background Semaglutide is highly | A5371) study, a single-arm study of semaglutide in | semaglutide for 24 weeks (titrated to 1 mg/week by week 4 | ).Conclusions In PWH receiving semaglutide for MASLD, despite | effective for decreasing weight. Concomitant loss of

关键词： obesity | muscle | function | HIV | semaglutide

摘要：Abstract Background Semaglutide 2.4 mg | estimated the US population eligibility for semaglutide | estimate the US eligible population. Semaglutide weight | in estimated risks with and without semaglutide | % “after” semaglutide “treatment” reflecting a 1.81

关键词： Obesity | Cardiovascular disease | Prevention | Semaglutide | GLP-1 receptor agonists

摘要： 643 million by the end of 2030. Semaglutide, a human | absorption efficiency of semaglutide in oral delivery, we | semaglutide. | Diabetes is now a global chronic disease, with | the number of people with diabetes expected to reach

关键词： semaglutide | oral delivery | diabetes | penetration enhancers

4008-161-200 800-990-8900

国家科技图书文献中心

摘要： influence of semaglutide, a glucagon-like peptide-1 | is achieved with semaglutide, the impact of this | investigations have demonstrated that semaglutide-induced | semaglutide. This disparity in research findings emphasizes | because semaglutide* use is rising quickly. (c) 2024*

摘要： mechanisms remain incompletely understood. Semaglutide, a | the therapeutic potential of semaglutide* in diabetic* | diet/streptozotocin were treated with semaglutide | effects of semaglutide* were analysed using animal and* | , semaglutide* alleviated metabolic disorders, ameliorated*

摘要：Background: Semaglutide, a glucagon-like | from initiation of semaglutide* compared with baseline* | -specific outcomes with and without semaglutide* use in* | semaglutide (mean age 47.4 +/- 12.2 years; mean TBW 237 | mean TBW change after initiation of semaglutide* in*

摘要： safety of Semaglutide* for non-diabetic obese patients* | meta-analysis of semaglutide* in non-diabetic obesity* | 10 RCTs, revealing that semaglutide* induced average* | rates significantly increased. Semaglutide* also* | obesity. However, Recent studies show semaglutide* can*

摘要： efficacy and safety of semaglutide* in weight loss in non* | people who used semaglutide* to lose weight in the* | semaglutide 0.25 mg, 0.5 mg, 0.75 mg, or 1 mg subcutaneously | hypotension, was observed. Conclusion Low-dose semaglutide | Objective The study aimed to investigate the

摘要： clinical trials reported that subcutaneous semaglutide | and 18,231 participants in the semaglutide* group* | were included in this study. Subcutaneous semaglutide | pressure-lowering property of subcutaneous semaglutide | semaglutide more than 1 mg/week, baseline systolic blood

摘要：Abstract Background Semaglutide* is highly* | A5371) study, a single-arm study of semaglutide* in* | semaglutide for 24 weeks (titrated to 1 mg/week by week 4 | ).Conclusions In PWH receiving semaglutide* for MASLD, despite* | effective for decreasing weight. Concomitant loss of

摘要：Abstract Background Semaglutide* 2.4 mg* | estimated the US population eligibility for semaglutide | estimate the US eligible population. Semaglutide* weight* | in estimated risks with and without semaglutide | % “after” semaglutide* “treatment” reflecting a 1.81*

摘要： 643 million by the end of 2030. Semaglutide, a human | absorption efficiency of semaglutide* in oral delivery, we* | semaglutide. | Diabetes is now a global chronic disease, with | the number of people with diabetes expected to reach